AstraZeneca: New drug data, promising earnings and a $3.5B R&D investment
AstraZeneca’s earnings were boosted by its oncology, cardiovascular, respiratory and immunology (R&I), and rare disease pipelines, the company said, with oncology seeing 22% growth. Cardiovascular, renal and metabolism (CVRM) experienced 21% growth, R&I 24% and rare disease 14%.
AstraZeneca invests $3.5B in US manfacturing, R&D
The company is also raising its full-year guidance to $14.9 billion in adjusted EBITDA, an 8.8% increase from its last projection. The U.S. is AstraZeneca’s largest market, generating 44% of its total revenue, according to its Q3 earnings presentation.
AstraZeneca PLC aims for $80 billion revenue by 2030 through strong growth in oncology, biopharmaceuticals, and rare diseases ...
Smith also points out that the focus on Dato-DXd has overshadowed AstraZeneca’s promising non-oncology pipeline, which is expected to deliver significant developments between 2025 and 2028.
The company believes Chinese authorities are probing allegations that two current and two former employees had illegally ...
AstraZeneca is set to report its third-quarter 2024 earnings Tuesday morning. The company's Q2 performance suggests strong ...
AstraZeneca’s growth was driven by its portfolio of products in the oncology, biopharmaceuticals and rare disease segments ...
AstraZeneca and Daiichi Sankyo have submitted a new Biologics License Application (BLA) for accelerated approval in the US ...
The adjusted EPS was $2.08 (1 ADR = 2 Common Shares). AstraZeneca’s top business, oncology, increased 19% (up 22% on ...
Zacks.com on MSN2d
AstraZeneca Beats on Q3 Earnings, Ups 2024 View, to Invest $3.5B in USAmong AstraZeneca’s various therapeutic areas, Oncology product sales were up 22%, while Cardiovascular, Renal and ...
AstraZeneca ( (AZN) ) has released its Q3 earnings. Here is a breakdown of the information AstraZeneca presented to its investors. AstraZeneca ...
Recent health news highlights include Amgen addressing bone density concerns, AstraZeneca revising its financial outlook ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback